CXCR4 and colorectal cancer: Oxaliplatin-resistant colorectal cancer cells strongly expressed CXCR4, and in vitro treatment with a CXCR4 antagonist mitigated treatment resistance and the downstream pathways involved, including PI3K/AKT and ERK1/2 intracellular signaling cascades and the NF-κB transcription factor 119.